Clinical Trial

INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

Study acronym: INSTA-MD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomised, double-blind, placebo-controlled clinical trial in which patients with major depressive disorder will receive augmentation through minocycline (MCO), celecoxib (CXB) or placebo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-08.
Status change: Not Yet Recruiting → Recruiting 2024-10-09
Trial Details
NCT Number NCT05644301
Lead Sponsor Universiteit Antwerpen
Collaborators: Research Foundation Flanders, KU Leuven, Vrije Universiteit Brussel, Amsterdam UMC, location VUmc
Conditions Major Depressive Disorder, Inflammation
Enrollment 240 participants
Start Date 2023-09-21
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-15